Norden Group LLC Acquires 157,604 Shares of Bristol Myers Squibb Company $BMY

Norden Group LLC raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 816.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 176,915 shares of the biopharmaceutical company’s stock after buying an additional 157,604 shares during the quarter. Bristol Myers Squibb accounts for about 0.9% of Norden Group LLC’s investment portfolio, making the stock its 17th largest position. Norden Group LLC’s holdings in Bristol Myers Squibb were worth $9,543,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Regatta Capital Group LLC bought a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $230,000. Olistico Wealth LLC bought a new position in Bristol Myers Squibb during the fourth quarter worth $65,000. SeaCrest Wealth Management LLC increased its position in Bristol Myers Squibb by 1.6% during the fourth quarter. SeaCrest Wealth Management LLC now owns 18,388 shares of the biopharmaceutical company’s stock worth $1,043,000 after acquiring an additional 294 shares during the period. Benin Management CORP raised its stake in Bristol Myers Squibb by 12.4% during the 4th quarter. Benin Management CORP now owns 9,063 shares of the biopharmaceutical company’s stock valued at $489,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Castleview Partners LLC boosted its holdings in Bristol Myers Squibb by 15.5% in the 4th quarter. Castleview Partners LLC now owns 85,542 shares of the biopharmaceutical company’s stock valued at $4,614,000 after purchasing an additional 11,504 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

NYSE:BMY opened at $59.40 on Friday. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The company has a 50-day moving average of $58.75 and a 200-day moving average of $52.11. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a market capitalization of $120.97 billion, a price-to-earnings ratio of 17.22, a PEG ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the previous year, the firm earned $1.67 EPS. The business’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

Analysts Set New Price Targets

Several research firms have recently issued reports on BMY. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 price objective (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Leerink Partners increased their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Scotiabank restated a “sector perform” rating and set a $60.00 price target (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Truist Financial set a $65.00 price target on Bristol Myers Squibb in a report on Wednesday, December 3rd. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $61.41.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.